Chemically modified thrombin and anhydrothrombin that differentiate macromolecular substrates of thrombin

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 12, 2005, Pages 2703-2711

  Hosokawa, K ^a,b   Ohnishi, T ^a,b   Kawakami, A ^a   Wakabayashi, S ^a   Koide, T ^a  

^a UNIVERSITY OF HYOGO   (Japan)

^b Fujimori Kogyo CO   (Japan)

Author keywords

Anhydrothrombin; Anticoagulant; Antiplatelet; Factor VIII; PAR1; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CARBOXYL GROUP; FIBRINOGEN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; FIBRIN CLOT; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION;

BLOOD COAGULATION; CARBOXYLIC ACIDS; FACTOR VIII; FIBRINOLYTIC AGENTS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; RECEPTOR, PAR-1; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THROMBIN;

EID: 29244463338     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01637.x     Document Type: Article

References (35)

1. Lorand L, Konishi K. Activation of the fibrin stabilizing factor of plasma by thrombin. Arch Biochem Biophys 1964; 105: 58-67.
2. Colman RW. The effect of proteolytic enzymes on bovine factor V. I. Kinetics of activation and inactivation by bovine thrombin. Biochemistry 1969; 8: 1438-45.
3. Fass DN, Knutson GJ, Katzmann JA. Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein. Blood 1982; 59: 594-600.
4. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-64.
5. 2+ responses of protease-treated human platelets activated with alpha-thrombin and the tethered ligand peptide. Biochemistry 1996; 35: 915-21.
6. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 1998; 95: 6642-6.
7. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-4.
8. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A 1999; 96: 11189-93.
9. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000; 39: 5458-67.
10. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
11. Adam F, Guillin MC, Jandrot-Perrus M. Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin. Eur J Biochem 2003; 270: 2959-70.
12. Yun TH, Baglia FA, Myles T, Navaneetham D, Lopez JA, Walsh PN, Leung LL. Thrombin activation of factor XI on activated platelets requires the interaction of factor XI and platelet glycoprotein Ib alpha with thrombin anion-binding exosites I and II, respectively. J Biol Chem 2003; 278: 48112-9.
13. Soslau G, Class R, Morgan DA, Foster C, Lord ST, Marchese P, Ruggeri ZM. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem 2001; 276: 21173-83.
14. Jarvis GE, Atkinson BT, Frampton J, Watson SP. Thrombin-induced conversion of fibrinogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb. Br J Pharmacol 2003; 138: 574-83.
15. Dubois C, Steiner B, Kieffer N, Reigner SC. Thrombin binding to GPIbalpha induces platelet aggregation and fibrin clot retraction supported by resting alphaIIbbeta3 interaction with polymerized fibrin. Thromb Haemost 2003; 89: 853-65.
16. Soslau G, Favero M. The GPIb-thrombin pathway: evidence for a novel role of fibrin in platelet aggregation. J Thromb Haemost 2004; 2: 522-4.
17. Nogami K, Shima M, Hosokawa K, Nagata M, Koide T, Saenko EL, Tanaka I, Shibata M, Yoshioka A. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000; 275: 25774-80.
18. Hosokawa K, Ohnishi T, Shima M, Nagata M, Koide T. Preparation of anhydrothrombin and characterization of its interaction with natural thrombin substrates. Biochem J 2001; 354: 309-13.
19. Vassallo RR Jr, Kieber-Emmons T, Cichowski K, Brass LF. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem 1992; 267: 6081-5.
20. Achyuthan KE, Dobson JV, Greenberg CS. Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen: inhibition of transglutaminase cross-linking. Biochim Biophys Acta 1986; 872: 261-8.
21. Lundblad RL, Kingdon HS, Mann KG. Thrombin. Methods Enzymol 1976; 45: 156-76.
22. Soslau G, Giles J. The loss of sialic acid and its prevention in stored human platelets. Thromb Res 1982; 26: 443-55.
23. Church FC, Pratt CW, Noyes CM, Kalayanamit T, Sherrill GB, Tobin RB, Meade JB. Structural and functional properties of human alpha-thrombin, phosphopyridoxylated alpha-thrombin, and gamma T-thrombin. Identification of lysyl residues in alpha-thrombin that are critical for heparin and fibrin(ogen) interactions. J Biol Chem 1989; 264: 18419-25.
24. Wells CM, Di Cera E. Thrombin is a Na(+)-activated enzyme. Biochemistry 1992; 31: 11721-30.
25. Di Cera E, Guinto ER, Vindigni A, Dang QD, Ayala YM, Wuyi M, Tulinsky A. The Na + binding site of thrombin. J Biol Chem 1995; 270: 22089-92.
26. Guinto ER, Vindigni A, Ayala YM, Dang QD, Di Cera E. Identification of residues linked to the slow → fast transition of thrombin. Proc Natl Acad Sci U S A 1995; 92: 11185-9.
27. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LL, Gibbs CS. Functional mapping of the surface residues of human thrombin. J Biol Chem 1995; 270: 16854-63.
28. Mengwasser KE, Bush LA, Shih P, Cantwell AM, Di Cera E. Hirudin binding reveals key determinants of thrombin allostery. J Biol Chem 2005; 280: 26997-7003.
29. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, Maraganore JM. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J Mol Biol 1991; 221: 1379-93.
30. Bode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 1: 426-71.
31. Furman MI, Liu L, Benoit SE, Becker RC, Barnard MR, Michelson AD. The cleaved peptide of the thrombin receptor is a strong platelet agonist. Proc Natl Acad Sci U S A 1998; 95: 3082-7.
32. Claytor RB, Michelson AD, Li JM, Frelinger AL III, Rohrer MJ, Garnette CS, Barnard MR, Krueger LA, Furman MI. The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. J Vasc Surg 2003; 37: 440-5.
33. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE, Andrade-Gordon P. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304: 855-61.
34. Derian CK, Maryanoff BE, Zhang HC, Andrade-Gordon P. Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs 2003; 12: 209-21.
35. Damiano BP, Derian CK, Maryanoff BE, Zhang HC, Gordon PA. RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev 21; 2003: 313-26.